TABLE 2.

Screening recommendations for C. trachomatis and N. gonorrhoeae by population group and anatomic site according to the CDC^a

Population group for Screening	Subpopulation for Screening	Infection type	Anatomic sites	Frequency
Women	All sexually active women <25 yrs of age and sexually active women >25 yrs of age at increased risk	CT	Urogenital Rectal; considered based on exposure and shared decision making Pharyngeal; none	Annual Retest 3 mo following treatment
		NG	Urogenital Rectal; considered based on exposure and shared decision making Pharyngeal; considered based on exposure and shared decision making
Heterosexual men	High-prevalence settings (e.g., STI clinic, correctional facilities, adolescent clinics, etc.)	CT	Urogenital; screening can be considered based on risk assessment Rectal; none	Frequency not defined
		NG	Screening is not recommended
Men who have sex with men		CT	Urogenital Rectal Pharyngeal; none	Annual Screening every 3 mo is indicated for those at increased risk and those taking HIV PrEP
		NG	Urogenital Rectal Pharyngeal
Transgender and gender-diverse persons	Screening recommendations based on anatomy	CT	Urogenital (cervical/vagina/vaginoplasty) Rectal; considered based on exposure and shared decision making Pharyngeal; none	Annual for those <25 yrs of age with a cervix or those >25 yrs, with a cervix, and at increased risk Undefined for rectal/pharyngeal screening
		NG	Urogenital (cervical/vagina/vaginoplasty) Rectal; considered based on exposure and shared decision making Pharyngeal; considered based on exposure and shared decision making

^aCT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; STI, sexually transmitted infection; PrEP, preexposure prophylaxis.